JG
KROS icon

Jain Global’s Keros Therapeutics KROS Stock Holding History

Jain Global’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$634K Buy
+59,209
New +$660K ﹤0.01% 1132
2025
Q2 		– Sell
-19,986
Closed -$204K – 1418
2025
Q1 		$204K Sell
19,986
-31,298
-61% -$363K ﹤0.01% 857
2024
Q4 		$812K Buy
+51,284
New +$2.66M 0.02% 356

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jain Global's KROS Position: Q2 2026 in Review

Jain Global opened a new position in Keros Therapeutics (KROS) in Q2 2026: 59,209 shares worth $634K. The stake represents ﹤0.01% of the portfolio and ranks #1132 among its holdings. This is a return to the name: Jain Global previously reported a position in KROS as recently as Q1 2025.

Jain Global first reported a position in KROS in Q4 2024 and has held it in 3 quarters since. The position peaked at $812K in Q4 2024. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Jain Global held 59,209 shares of Keros Therapeutics worth $634K as of Q2 2026.
  • Keros Therapeutics was a new Jain Global position in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Jain Global's portfolio in Q2 2026, its #1132 holding.
  • Jain Global first reported a position in Keros Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Jain Global's Keros Therapeutics position peaked at $812K in Q4 2024.
  • 133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.